Octreotide Scan



  1. Gastro-entero-pancreatic neuroendocrine tumours (GEP-NET)

  2. Pituitary adenomas

  3. Tumours origination in a sympathetic system; pheochromocytoma, paraganglioma, neuroblastoma, ganglioneinoma etc.

  4. Medullary carcinoma of thyroid


Tc-99m Tektrotyd 9HYNIC-[D-Phel, Tyr3-Octreotide]) is intended for identifying pathological lesions in which over expression of somatostatin receptors occurs (especially subtype 2 and, to a lesser extent, subtypes 3 and 5). ) Tc-99m Tektrotyd attaches to somatostatin receptors in tissues where, as a consequence of the disease, the cell surfaces contain these receptors in more than the physiological density.

Preparation and Procedure:

  • Short acting somatostatin analogues should be stopped 3 days prior to the scan.

  • Lanreotide (long acting analogue) should be stopped at least 3 weeks prior to the scan.

  • Octreotide (long acting analogue) should be stopped at least 5 weeks prior to the scan.

  • A light diet the day before the examination, patient should fast on the day of examination until the end of the study.

  • Patients should increase fluids and empty their bladders frequently.

  • If the patient does not have diarrhoea a laxative should be taken the day before the scan.

  • Scanning is performed at 2 and 4 hours post injection; this includes whole body imaging and SPECT/CT.


  • Radiolabeled tracers provide a functional imaging technique to identify neuroendocrine tumours. Currently there are several single-photon techniques available using either 123I-MIBG, 111In-DTPA-pentetreotide (Octreoscan) or 99mTc-EDDA/HYNIC-try3-octreotate. While this is an expensive procedure and has only a limited role in the assessment of these tumours, it can be useful in treatment planning.

rounded corners top

Related Documents

rounded corners bottom
Page last reviewed: 16 January 2015